<DOC>
	<DOCNO>NCT00774072</DOCNO>
	<brief_summary>The purpose study determine whether nasal inhalation GernebcinÂ® effective decrease Pseudomonas aeruginosa bacterial count nasal lavage fluid .</brief_summary>
	<brief_title>Nasal Inhalation Tobramycin Patients With Cystic Fibrosis Pseudomonas Aeruginosa Colonization</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pseudomonas Infections</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<criteria>subject confirm diagnosis cystic fibrosis detection P. aeruginosa nasal lavage ( culture ) chronic P.a . colonization lung ( day 28 ) inform consent patient parent subject old 7 year subject able comply inhalation procedure nasal lavage procedure schedule protocol woman childbearing potential include study , use effective method birth control protocol subject critical condition define : FEV1 &lt; 30 % / SaO2 &lt; 93 % without O2substitution ; need O2substitution subject ENT surgery within 3 month prior study subject show sign nasal bleed subject ear drum perforation subject acute rhinosinusitis pulmonary exacerbation study entry need additional systemic antibiotic therapy pseudomonas aerug . subject unlikely comply procedure schedule protocol subject know allergic reaction medication subject pregnant breastfeeding subject participate another clinical trial within 30 day prior study entry 30 day end study . systemic ( oral intravenous ) antibiotic treatment P.a . 14 day prior inclusion study serum level tobramycin 2 mg/l one hour inhalation , subject withdraw participation study . progress renal insufficiency severe damage N. acusticus dizziness ( potential damage . N. vestibularis )</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>subject cystic fibrosis pseudomonas aeruginosa colonization upper airway</keyword>
</DOC>